Looking the part: Launchpoint finds new home to showcase growing business
It has been a few years since Launchpoint Electric Propulsion Solutions struck out on its own, being spun out of the now-defunct Launchpoint Technologies, but now, the company is ready for takeoff. Launchpoint EPS moved into its new facility at 320 Storke Rd. in early August, upping its presence in the region for the new Read More →
Federal funding allocated to disaster recovery efforts
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Our view: Ramirez legacy endures with archive at CSUCI
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
CRE: Equity Union purchases Westlake Village location for new branch
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Oxnard firm helps area cities meet new climate rules
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Opinion: Witness to or maker of history
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
FTC settles lawsuit, paves way for Amgen’s $28B purchase of Horizon Therapeutics
The Federal Trade Commission entered into a consent agreement with Amgen and Horizon Therapeutics, clearing the way for Amgen’s $28 billion acquisition of Horizon to go through. Announced on Sept. 1, Amgen agreed to not use its drug list to inhibit competition for Tepezza and Krystezza, which are Horizon’s biggest two drugs and the only Read More →
